Know Labs has received a new foundational patent in the US that equates its Bio-RFID diagnostic technology to the existing glucose monitoring standard.
The US-based medical diagnostic technology developer said that the patent establishes a benchmark of clinical accuracy, dubbed as Mean Absolute Relative Difference (MARD).
According to the firm, blood glucose reading with its Bio-RFID technology is different from already existing US Food and Drug Administration (FDA)-cleared devices. The technology uses radio frequency spectroscopy to collect data signals from the concentrations of glucose in the interstitial fluid, capillary and venous blood, and cellular tissue in real time.
This capability is improved by time-frequency synchronisation and decoupled antenna designs. According to internal calculations, Know Labs’ sensor penetrates to an average depth of 0.5in at 16mW at 2.5 GHz, the medical diagnostic firm said.
The United States Patent and Trademark Office has granted US Patent No. 11,529,077, titled “High Performance Glucose Sensor” to the technology.
The new patent is said to strengthen Know Labs’ position as a global IP holder in non-invasive blood glucose monitoring by bringing the company’s total number of issued and pending patents to almost 90.
Know Labs founder and chairman Ron Erickson said: “Intellectual property development is a critical pillar of our success.
“We make significant investments in the strategic development of our IP Portfolio, which creates long-term value for our shareholders, improves our competitive position and accelerates our efforts to bring the first FDA-cleared, truly non-invasive glucose monitoring device to the market.”
This patent specifically designates a MARD range of 5% to 9.9% for the non-invasive diagnostics platform of the company.
Know Labs claimed that the range covered by the patent for its Bio-RFID technology is equal to or superior to the MARD readings of any blood glucose monitoring products cleared by the FDA.
